Psyence BioMed's Texas Subsidiary Secures Exclusive U.S. Ibogaine License from Related-Party PsyLabs
PBM has more than doubled off its 52-week low of $1.92.
Summary
Psyence BioMed's Texas subsidiary TIRC signed a binding term sheet with related-party PsyLabs for exclusive U.S. rights to develop, supply, and distribute pharmaceutical-grade ibogaine, with a definitive agreement due by November 30, 2026.
Key Events · M&A and Partnerships · PBM
-
Exclusive U.S. Ibogaine License Secured
TIRC, Psyence BioMed's wholly-owned Texas subsidiary, entered into a binding term sheet with PsyLabs granting exclusive U.S. license, supply, and wholesale distribution rights to PsyLabs' pharmaceutical-grade ibogaine hydrochloride.
-
Financial Terms Disclosed
TIRC will pay up to approximately US$1.3 million in development and regulatory milestone payments for the first drug candidate, an annual exclusivity fee after first FDA approval, a low single-digit royalty on net sales, and a margin-sharing arrangement on resales.
-
Related-Party Transaction
PsyLabs is a significant shareholder of Psyence BioMed, Psyence BioMed holds an ownership interest in PsyLabs, and certain management members are affiliates of PsyLabs with financial interests in it.
-
Definitive Agreement Deadline
The binding term sheet will automatically lapse if a definitive agreement is not signed by November 30, 2026, unless extended by written agreement.
Analysis · PBM · Life Sciences
A binding term sheet between Psyence BioMed's wholly-owned Texas subsidiary, TIRC, and PsyLabs—a significant shareholder in which Psyence BioMed also holds an ownership interest—grants TIRC exclusive U.S. rights to develop, manufacture, and commercialize pharmaceutical-grade ibogaine. The deal gives TIRC a defined position in U.S. ibogaine development, backed by PsyLabs' manufacturing know-how and technical documentation. However, the arrangement is a related-party transaction, and the terms may differ from those that would be agreed between unrelated parties. The term sheet is binding but will lapse if a definitive agreement is not signed by November 30, 2026, leaving execution risk. For a company with a market cap of approximately $21 million, the up to $1.3 million in milestone payments is a meaningful commitment, but the exclusive U.S. rights could be transformative if ibogaine development advances.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBM was trading at $5.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $1.92 to $28.13. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.